Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity

Wen Ye¹,²,³,⁵, Cui Chen¹,⁵, Ying Gao¹,⁵, Zou-Shan Zheng¹, Yi Xu¹, Miao Yun¹, Hui-Wen Weng¹, Dan Xie²,³, Sheng Ye*¹ and Jia-Xing Zhang*¹,²

Solute carrier family 34 member 2 (SLC34A2), a pH-sensitive sodium-dependent phosphate transporter, is associated with several human cancers. In this study, we investigate the clinical significance of SLC34A2 and its function in human bladder cancer (BC). The expression dynamics of SLC34A2 were examined in two independent cohorts of BC samples by quantitative PCR, western blotting and immunohistochemical staining. In the training cohort (156 cases), we applied the X-tile program software to assess the optimal cutoff points for biomarkers in order to accurately classify patients according to clinical outcome. In the validation cohort (130 cases), the cutoff score derived from X-tile analysis was investigated to determine the association of SLC34A2 expression with survival outcome. A series of in vitro and in vivo assays were then performed to elucidate the function of SLC34A2 in BC and its underlying mechanisms. Results showed that SLC34A2 was significantly upregulated in BC cell lines and clinical samples. In both two cohorts of BC samples, high expression of SLC34A2 was associated with large tumor size, advanced T status and poor patients’ survival. The depletion of SLC34A2 in BC suppressed cellular viability, colony formation and anchorage-independent growth in vitro, and inhibited xenograft tumor growth in vivo, whereas overexpression of SLC34A2 had the converse effect. Simultaneously, downregulation of SLC34A2 decreased the transcriptional activity and protein expression level of c-Myc in BC cells, whereas restoration of c-Myc expression could compromise the anti-proliferation effect of SLC34A2 depletion. Furthermore, miR-214 was proved as a negative regulator of SLC34A2. Our present study illustrated that SLC34A2 has an important role in promoting proliferation and tumorigenicity of BC, and may represent a novel therapeutic target for this disease.

Cell Death and Disease (2017) 8, e2581; doi:10.1038/cddis.2017.13; published online 2 February 2017

1Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China; 2The State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; 3Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China and 4Department of Ultrasound, Sun Yat-Sen University Cancer Center, Guangzhou, China

*Corresponding author: S Ye or J-X Zhang, Department of Oncology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan road II, Guangzhou 510080, China. Tel/Fax: 86 20 87755766; E-mail: yes20111212@163.com or zjxlundy@hotmail.com

5These authors contributed equally to this work.

Received 24.10.16; revised 25.12.16; accepted 03.1.17; Edited by A Oberst
promote tumorigenic and self-renewal potential of CD166(+) lung cancer stem cell-like cells through Wnt/β-catenin pathway. Unlike the situation in lung cancer, it is widely accepted that SLC34A2 is upregulated in ovarian cancer, especially in well-differentiated tumors. Furthermore, enhanced SLC34A2 expression was reported to be correlated with chemo-response and survival of breast cancer patients, and downregulation of SLC34A2 could sensitize breast cancer stem cells to doxorubicin. Meanwhile, SLC34A2 is downregulated in renal cell carcinoma because of promoter methylation. Thus, SLC34A2 is dysregulated and acts as either an oncogene or tumor-suppressor gene in different cancers. Up to date, however, the expression dynamics of SLC34A2 in BC and its clinicopathologic/prognostic significance have not been elucidated. Therefore, it is of great significance to explore the role of SLC34A2 in BC.

In this study, we aimed to identify the expression status of SLC34A2 in BC cell lines and tissues. We next proceeded to investigate the SLC34A2 expression pattern in two different cohorts of BC patients who underwent radical cystectomy. Furthermore, the function of SLC34A2 to the pathogenesis and progression of BC were explored. We report for the first time that SLC34A2, a target of miR-214, is obviously upregulated in BC, and serves as an independent prognostic indicator for BC patients. Moreover, SLC34A2 promotes BC cell proliferation and tumor growth both in vitro and in vivo, which is achieved via upregulating expression level and transcriptional activity of c-Myc.

Results

Elevated expression of SLC34A2 in BC. To investigate the expression status of SLC34A2 in BC, western blotting and quantitative RT-PCR analyses were performed in four BC cell lines (EJ, T24, 5637 and BIU-87), three normal bladder tissues and five fresh BC tissues paired with their adjacent non-neoplastic bladder tissues (ANTs). As shown in Figure 1a, SLC34A2 were significantly upregulated in all four BC cell lines compared with normal bladder tissues both on protein and mRNA levels. Similarly, SLC34A2 were considerably higher in BC tissue specimens when compared with their paired ANTs (Figure 1b). We then conducted immunohistochemical (IHC) assays in two independent cohorts of BC tissue slices to determine the protein level of SLC34A2. Representative staining of SLC34A2 in BC tissue is shown in Figures 1c-f. The positive staining is observed in the membrane and cytoplasm of BC cells. Analogously, IHC assays revealed a similar expression pattern of SLC34A2 in BC and the corresponding ANTs, where SLC34A2 was overexpressed in BC tissue.

Selection of cutoff score for high expression of SLC34A2 in BC. To assess the statistical significance and avoid arbitrary cut point selection, we applied the X-tile program to obtain cutoff scores for SLC34A2 expression. Using the X-tile plots for the training cohort, we divided this cohort into low and high populations based on a cutoff score of ‘2.1’ for SLC34A2 IHC staining (Figure 2a). This optimal cut point determined by the training cohort was then applied to the validation cohort, which identified the cutoff score to have high statistical significance again (P<0.001; Figure 2b). According to this cut point, high SLC34A2 expression was observed in 82 of 156 (52.6%) BCs and 8 of 50 (16%) adjacent non-neoplastic bladder tissues (ANTs) in the training cohort (P<0.001). In the validation cohort, high SLC34A2 expression was observed in 71 of 130 (54.8%) BC cases.

The rates of high expression of SLC34A2 in BC with respect to clinicopathologic features were detailed in Table 1. We observed that high expression of SLC34A2 was positively associated with larger tumor size (P=0.017; P=0.012, respectively) and advanced T status (P<0.001; P=0.008, respectively) both in training and validation cohorts of BC cases (Table 1). These data suggested that the expression of SLC34A2 increases with BC progression.

Elevated SLC34A2 expression predicted poor prognosis. To further confirm the prognostic value of SLC34A2 expression and clinicopathological features in BC, we applied receiver operating characteristic (ROC) curves to test patient survival status in our study. According to the ROC curve analysis, SLC34A2 was found to be a promising predictor for survival status both in training (area under the curve (AUC)=0.658; P=0.001) and validation cohort (AUC=0.692; P<0.001; Figure 2c). Furthermore, our univariate and multivariate analysis showed that high expression of SLC34A2 was an independent risk factor for adverse overall survival (OS) in both training (hazard ratio (HR): 3.006; 95% confidence interval (CI): 1.333–4.1934, P=0.003; Table 2) and validation cohorts (HR: 2.364, 95% CI: 1.333–4.1934, P=0.003; Table 2). In addition, survival analysis illustrated that SLC34A2 expression could significantly stratify OS in a subset of BC patients with different age, gender, T status, N status, overall clinical stage, tumor grade and tumor size (Supplementary Figure 1).

Effects of SLC34A2 on cell proliferation in vitro. Two short hairpin RNAs (shRNAs) specifically directed against SLC34A2 (shSLC34A2) were induced into EJ and T24 cell lines, which exhibit high SLC34A2 expression, whereas exogenous SLC34A2 was stably introduced into 5637 cell, which shows relative low SLC34A2 expression (Figure 3a). Next, MTT assays and colony formation assays were used to assess the effects of SLC34A2 on cell viability and proliferation ability. EJ and T24 cells transfected with shSLC34A2 showed significant growth inhibition compared with scramble controls (P<0.001), and overexpression of SLC34A2 promoted the growth of 5637 cells compared with negative control cells (P<0.001; Figure 3b). Fewer and smaller colonies were observed in shSLC34A2 treated cells when compared with scramble controls (P<0.001); whereas overexpression of SLC34A2 resulted in more and larger colonies compared with control cells (P<0.001; Figure 3c). Furthermore, we use anchorage-independent growth ability assay of soft agar to determine the ability of SLC34A2 in malignancy transforming. Results showed that downregulation of SLC34A2 greatly suppressed the anchorage-independent growth of both EJ and T24 cells (P<0.001), but upregulation of SLC34A2 significantly accelerated the malignancy.
transforming growth of 5637 cells ($P<0.001$; Figure 3d).

Taken together, these results suggested the pro-proliferative role of SLC34A2 in human BC cells in vitro. We further examined the relationship between SLC34A2 and Ki-67 expression in BC tissues, as the latter is a marker for cellular proliferation. We observed that BC cases with high SLC34A2 expression also exhibited strong Ki-67 staining signals, whereas those with low levels of SLC34A2 displayed weak Ki-67 staining (Figure 3e). The chi-square testing showed a significant correlation between SLC34A2 expression and the Ki-67 labeling index in BC ($P<0.001$; Figure 3e).

**Effects of SLC34A2 on tumor growth in vivo.** To further confirm the effect of SLC34A2 required for BC tumor growth in vivo, xenograft tumor model assays were conducted by injecting EJ-shSLC34A2/scramble cells and 5637-SLC34A2/control cells into the dorsal flank of nude mice subcutaneously. The EJ/shSLC34A2 cells grew at a much slower rate than EJ/scramble cells, whereas SLC34A2 overexpression accelerated the xenograft tumor growth ($P<0.001$; Figure 4a). Furthermore, the average weight of tumor was significantly lower in the SLC34A2 depletion group compared with the EJ/scramble group ($P<0.001$), whereas overexpression of SLC34A2 in 5637 cells largely increased the tumor burden ($P<0.001$; Figure 4b). Collectively, this gave direct evidence of SLC34A2’s role in promoting BC carcinogenesis in vivo.

**Depletion of SLC34A2 suppressed the expression and transcription capacity of c-Myc.** As c-Myc is a critical transcription factor, which binds target DNA sequences to regulate transcription of genes involved in cell growth and proliferation, we further explored the transcription capacity of c-Myc using dual-luciferase reporter assay in the presence of shSLC34A2. As shown in Figure 5a, the relative luciferase reporter activity was remarkably decreased in SLC34A2-silenced cells. Interestingly, we also noticed the depletion of SLC34A2 by shRNAs suppressed the expression of c-Myc simultaneously in both EJ and T24 cells by the western blotting (Figure 5b) and immunofluorescence analysis (Figure 5c). Furthermore, our IHC analysis illustrated that expression levels of SLC34A2 and c-Myc proteins were positively correlated in the total BC cases enrolled ($r=0.821$, $P<0.001$; Figure 5d). These data suggest that c-Myc is closely linked with SLC34A2, it may involve in SLC34A2-related cell growth and proliferation.

To confirm these results, exogenous c-Myc was induced into EJ/T24 shSLC34A2–1 cells, in which endogenous c-Myc were greatly downregulated in the presence of shSLC34A2–1 (Figure 5e). As shown in Figures 5f and g, the inhibition of cell viability and proliferation ability by shSLC34A2 was significantly compromised by treatment with exogenous c-Myc, as determined by MTT assays and colony formation assays. Taken together, these data indicate that SLC34A2 enhances tumor cell growth and proliferation through upregulation of c-Myc, which is a well-known oncogenic factor.
MiR-214 is a negative regulator of SLC34A2. As post-translational regulation such as microRNA (miRNA) had critical role in protein regulation, we sought to explore whether the dysregulation of miRNAs was responsible for the upregulation of SLC34A2 in BC. We first conducted bioinformatics analyses and overlapped the predicted miRNA

Figure 2: The selection of optimal cutoff value for SLC34A2 IHC score in two different cohorts of BC samples. (a) X-tile analysis was conducted on patient data from the training cohort, equally subdivided into training and validation subsets. X-tile plots of training sets are displayed in the left panels, with matched validation sets in the smaller inset. The plot showed the $\chi^2$ log-rank values created when the cohort was divided into two populations. The cut point was demonstrated on a histogram of the entire cohort (middle panels) and a Kaplan–Meier plot (right panels). $P$-values were defined by using the cut point derived from a training subset to parse a separate validation subset. SLC34A2 expression was divided at the optimal cut point (for high expression, $n=82$; for low expression, $n=74$), where the plot achieves highest significance (with positive staining of SLC34A2; $P<0.001$). (b) The optimal cut point for SLC34A2 expression determined by X-tile plot of the testing cohort was applied to the validation cohort (for high expression, $n=71$; for low expression, $n=59$) and reached high statistical significance ($P<0.001$). (c) ROC curve analysis for different clinicopathological features and SLC34A2 expression was performed to evaluate the survival status. Left panel: age (AUC = 0.455; $P = 0.338$), gender (AUC = 0.539; $P = 0.406$), grade (AUC = 0.533; $P = 0.478$), tumor size (AUC = 0.566; $P = 0.064$), T stage (AUC = 0.565; $P = 0.166$), N stage (AUC = 0.540; $P = 0.390$), tumor multiplicity (AUC = 0.583; $P = 0.046$) and SLC34A2 expression (AUC = 0.658; $P = 0.001$) implied statistical associations with survival in the training cohort; Right panel: age (AUC = 0.446; $P = 0.289$), gender (AUC = 0.492; $P = 0.880$), grade (AUC = 0.592; $P = 0.069$), tumor size (AUC = 0.654; $P = 0.002$), T stage (AUC = 0.623; $P = 0.015$), N stage (AUC = 0.569; $P = 0.173$), tumor multiplicity (AUC = 0.585; $P = 0.050$) and SLC34A2 expression (AUC = 0.692; $P < 0.001$) were used to test the survival status in validation cohort.
regulators with downregulated miRNAs from miRNA expression profiles of BC. The result showed that miR-214 was singled out as a potential regulator of SLC34A2 (Figure 6a). Next, our quantitative RT-PCR analyses showed that miR-214 was indeed downregulated in all four BC cell lines and five fresh BC tissues examined (Figure 6b). To verify the hypothesis that downregulation of miR-214 was responsible for the upregulation of SLC34A2 in BC, we constructed miR-214 mutant (miR-214-mut), which mismatched the 3'-UTR of SLC34A2 (Figure 6c). Results of the luciferase reporter assay showed that miR-214 overexpression decreased the luciferase activity of the SLC34A2 3'-UTR, whereas the miR-214-mut failed to show an inhibitory effect on the luciferase expression (Figure 6d). Furthermore, western blotting assays proved that miR-214 greatly downregulated the protein level of SLC34A2, whereas miR-214-mut exerted none of the above effects (Figure 6e). These data collectively provided evidence that miR-214 directly suppresses SLC34A2 expression and decreased miR-214 contributes to SLC34A2 overexpression in BC.

**Discussion**

According to National Central Cancer Registry of China 2015 annual report, the incidence of BC in male cancers was 7.68/10⁵ in 2011, and the mortality rate was 3.03/10⁵, which ranked sixth and tenth amount all cancers, respectively. Chinese Bladder Cancer Consortium reported that surgical therapies especially transurethral resection and radical cystectomy are generally applied for non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). About 70% of the NMIBC patients accepted chemotherapy instillation, and 20.3% MIBC patients accepted neo-adjuvant or adjuvant chemotherapy. However, the long-term prognosis of BC patients remains unsatisfactory. Five-year cumulative intravesicle recurrence is about 35% in NMIBC, whereas MIBC patients have a 5-year overall survival of about 60%. Thus, there is an urgent need to identify biomarkers, which can be used to define the malignancy potential of BC or as potential therapeutic targets.

In this study, we sought to explore the role of SLC34A2 in human BC. We report, for the first time, that the expression of SLC34A2 is pervasively upregulated in BC cell lines and tissues. Furthermore, high expression of SLC34A2 in BC is a strong marker for poor prognosis. These results indicate that SLC34A2 has a critical role in BC carcinogenesis and may facilitate highly malignancy transforming. As a widely accepted fact, advanced stage of tumor and recurrence are major causes of cancer-related death. Notably, our analyses demonstrated that high level of SLC34A2 was significantly correlated with advanced T stage and larger tumor size. In consistent, our *in vitro* and *in vivo* studies showed that overexpression of SLC34A2 increased cellular viability and proliferation ability, but the deletion of SLC34A2 repressed

| Variables          | Training cohort | Validation cohort |          |
|--------------------|----------------|-------------------|----------|
|                    | Case Low expression | Case Low expression |          |
|                    | High expression | High expression |          |
|                    | P-value | Case Low expression | Case Low expression |          |
|                    |          | High expression |          |
|                    | P-value |          |          |
| Age                | Age     | Age             |          |
| ≤ 57               | 77      | 43 (55.8%)      |          |
| > 57               | 79      | 39 (49.4%)      |          |
| Gender             | Gender  | Gender          |          |
| Male               | 127     | 66 (52.0%)      |          |
| Female             | 29      | 16 (55.2%)      |          |
| WHO grade          | WHO     | WHO             |          |
| G1/2               | 77      | 45 (58.4%)      |          |
| G3                 | 79      | 37 (46.8%)      |          |
| Tumor size (cm)    | Tumor   | Tumor           |          |
| ≤ 5                | 75      | 32 (42.7%)      |          |
| > 5                | 81      | 30 (41.6%)      |          |
| T status           | T       | T               |          |
| T1/2               | 49      | 14 (28.6%)      |          |
| T3/4               | 107     | 68 (63.6%)      |          |
| N status           | N       | N               |          |
| N0                 | 125     | 63 (50.4%)      |          |
| N1/2               | 31      | 19 (61.3%)      |          |
| Tumor multiplicity | Tumor   | Tumor           |          |
| Unifocal           | 61      | 37 (60.7%)      |          |
| Multifocal         | 95      | 45 (47.4%)      |          |

| aMean age          | bMean tumor size |         |
|--------------------|------------------|---------|
| cStatistically significant difference |          |
these abilities. We take this promotion of tumor growth as a potential underlying mechanism in SLC34A2-mediated BC carcinogenesis. Thus, SLC34A2 expression may be a potential marker for malignancy of BC and an intervention target for treatment, that is, it implies that patients with high expression of SLC34A2 may need chemoradiation or molecular target therapy for tumor control after radical cystectomy, whereas those with low expression of SLC34A2 can avoid unnecessary treatments except for surgery. A mouse monoclonal antibody MX35 targeting SLC34A2 protein developed by Kiyamova et al. have provided data on the pattern of SLC34A2 expression and cellular localization in human breast, lung and ovarian cancers. However, the origin of murine limited the antibody’s full therapeutic potential. To overcome this impediment, a humanized antibody version named Rebmab200 was then developed. Analyses of Rebmab200 antibody demonstrated that it had strong reactivity with the tested tumor types but little or no reactivity with the tested normal tissues. A translational phase I clinical trials of Rebmab200 are now in progress. Thus, targeted therapy with SLC34A2 antibody in BC may be a viable option and deserve further testing in the near future.

Table 2 Univariate and multivariate analysis of SLC34A2 expression and various clinicopathological parameters in training and validation cohort patients with BC

| Variables                  | Training cohort | Validation cohort |
|----------------------------|-----------------|-------------------|
|                            | Case | HR  | 95% CI   | P-value | Case | HR  | 95% CI   | P-value |
| **Univariate analysis**    |      |     |          |         |      |     |          |         |
| Age                        |      |     |          |         |      |     |          |         |
| <60                        | 77   | 1.0 | 0.541–1.386 | 0.549  | 63   | 1.0 | 0.457–1.214 | 0.238  |
| >60                        | 79   | 0.866 | 0.541–1.386 | 0.549  | 67   | 0.745 | 0.457–1.214 | 0.238  |
| Gender                     |      |     |          |         |      |     |          |         |
| Female                     | 127  | 1.0 | 0.782–2.387 | 0.273  | 97   | 1.0 | 0.563–1.742 | 0.973  |
| Male                       | 29   | 1.366 | 0.782–2.387 | 0.273  | 33   | 0.99 | 0.563–1.742 | 0.973  |
| WHO grade                  |      |     |          |         |      |     |          |         |
| G1/2                       | 77   | 1.0 | 0.915–2.665 | 0.102  | 72   | 1.0 | 1.029–2.737 | 0.038b |
| G3                         | 79   | 1.562 | 0.915–2.665 | 0.102  | 58   | 1.678 | 1.029–2.737 | 0.038b |
| Tumor size (cm)            |      |     |          |         |      |     |          |         |
| ≤5                         | 61   | 1.0 | 1.133–2.981 | 0.014b | 61   | 1.0 | 1.497–4.129 | <0.001b |
| >5                         | 55   | 1.838 | 1.133–2.981 | 0.014b | 55   | 2.487 | 1.497–4.129 | <0.001b |
| N status                   |      |     |          |         |      |     |          |         |
| N0                         | 125  | 1.0 | 0.948–2.833 | 0.077  | 101  | 1.0 | 1.032–3.016 | 0.038b |
| N1                         | 31   | 1.639 | 0.948–2.833 | 0.077  | 29   | 1.764 | 1.032–3.016 | 0.038b |
| Tumor multiplicity         |      |     |          |         |      |     |          |         |
| Unifocal                   | 61   | 1.0 | 1.028–2.866 | 0.039b | 49   | 1.0 | 1.007–2.941 | 0.047b |
| Multifocal                 | 95   | 1.717 | 1.028–2.866 | 0.039b | 81   | 1.721 | 1.007–2.941 | 0.047b |
| SLC34A2 expression         |      |     |          |         |      |     |          |         |
| Low expression             | 74   | 1.0 | 1.737–4.850 | <0.001b | 59   | 1.0 | 1.915–5.828 | <0.001b |
| High expression            | 82   | 2.902 | 1.737–4.850 | <0.001b | 71   | 3.34 | 1.915–5.828 | <0.001b |
| Multivariate analysis      |      |     |          |         |      |     |          |         |
| Tumor size (cm)            |      |     |          |         |      |     |          |         |
| ≤5                         | 75   | 1.0 | 0.997–2.702 | 0.051  | 68   | 1.0 | 1.313–3.920 | 0.003b |
| >5                         | 81   | 1.642 | 0.997–2.702 | 0.051  | 62   | 2.269 | 1.313–3.920 | 0.003b |
| WHO grade                  |      |     |          |         |      |     |          |         |
| G1/2                       | 77   | 1.0 | 1.014–3.374 | 0.045b | 72   | 1.0 | 1.057–4.768 | 0.035b |
| G3                         | 79   | 1.809 | 1.014–3.374 | 0.045b | 58   | 1.261 | 1.057–4.768 | 0.035b |
| SLC34A2 expression         |      |     |          |         |      |     |          |         |
| Low expression             | 74   | 1.0 | 1.206–3.415 | 0.008b | 59   | 1.0 | 0.789–2.390 | 0.247  |
| High expression            | 82   | 3.006 | 1.746–5.172 | <0.001b | 71   | 2.364 | 1.746–5.172 | <0.001b |

**Abbreviations:** CI, confidence interval; HR, hazard ratio; P, P-value.

Cell Death and Disease
remarkably decreased. When exogenous c-Myc was induced into EJ/T24 shSLC34A2−1 cells, the inhibition of cell viability and proliferation ability exerted by decreased SLC34A2 was significantly compromised. Thus, we conclude that SLC34A2 enhances tumor cell growth and proliferation through upregulation of c-Myc, which is a well-known oncogenic factor. It expands another alternative strategy to inhibit cancer progression initiated by SLC34A2 in BC, that is,
to target the signaling mechanisms, by the use of c-Myc inhibitors.

As the expression of SLC34A2 is pervasively upregulated in BC cell lines and tissues, one critical question was then raised: what is the mechanism by which SLC34A2 is upregulated? A class of miRNAs has been proved as important regulators of gene expression,\(^\text{28,29}\) in this study with the help of bioinformatics analyses and miRNA expression profiles of BC cells,\(^\text{30}\) we revealed that miR-214 directly suppresses SLC34A2 expression and decreased miR-214 contributes to SLC34A2 overexpression in BC. This finding is based on evidence as below: first, miR-214 has a conserved binding site in the 3'-UTR of SLC34A2; second, the luciferase activity of SLC34A2 3'-UTR reporter is specifically responsive to increased miR-214 but non-reactive to miR-214-mut; third, the overexpression of miR-214 reduced the expression of SLC34A2; and fourth, miR-214 is downregulated in BC cells. Therefore, upregulation of miR-214, such as using miR-214 mimics, is an optional strategy to suppress BC, which has high level of SLC34A2.

In conclusion, we report for the first time that SLC34A2, target of miR-218, is overexpressed pervasively in BC, and it is correlated with poor prognosis, advanced T stage and larger tumor size. Furthermore, the deletion of SLC34A2 repressed carcinogenesis of BC cells both in vitro and in vivo through inhibiting the expression and transcription capacity of c-Myc. These findings suggest that SLC34A2 has role in the development and progression of human BC, which render SLC34A2 a potential prognostic marker and may serve as a novel therapeutic target in BC patients.

Materials and Methods
Cell lines and stable cell line construction. The human BC cell lines EJ, T24, 5637 and BIU-87 were grown in RPMI-1640 medium according to American Type Culture Collection (ATCC, Manassas, VA, USA) instructions.

Figure 4 Effects of SLC34A2 on tumor growth in vivo. (a) The xenograft tumor volumes of nude mice injected with EJ/scramble cells or EJ/shSLC34A2 cells (n = 6), and that of nude mice injected with 5637/control cells or 5637/SLC34A2 cells (n = 5). (b) The average tumor weight in nude mice injected with EJ/shSLC34A2 cells were significantly decreased compared with the EJ/scramble group (n = 6), whereas 5637 cells with overexpressed SLC34A2 largely increased the tumor burden (n = 5).

*P < 0.05

Figure 5 Depletion of SLC34A2 suppressed the expression and transcription capacity of c-Myc. (a) The luciferase reporter activities of c-Myc were remarkably decreased in SLC34A2-silenced EJ and T24 cells. (b and c) In SLC34A2 stably reduced EJ and T24 cells, the protein expression of c-Myc was decreased as determined by (b) western blotting analysis and (c) immunofluorescence staining. (d) Left panel: expression of SLC34A2 is positively associated with c-Myc in clinical BC specimens. Two representative cases are shown. Right panel: Pearson's correlation coefficients analysis showed that SLC34A2 positively correlated with c-Myc expression in BC samples. (e) In both EJ and T24 cells, endogenous c-Myc were greatly downregulated in the presence of shSLC34A2–1, the suppression was reversed by inducing exogenous c-Myc. (f-g) The inhibition of cell viability and proliferation ability by shSLC34A2 was significantly compromised by treatment with exogenous c-Myc, as determined by (f) MTT assays and (g) colony formation assays.

*P < 0.05
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). All cell lines were cultured in a humidified chamber with 5% CO₂ at 37 °C. All experiments were performed in cultures that were 70–80% confluent, the cells in log-phase growth.

The two shRNA used to repress SLC34A2 expression and the coding sequences of SLC34A2 expression vector are purchased from GeneCopoeia (Guangzhou, China). Vector construction, lentivirus production and infection were conducted as previously described.30

Cell Death and Disease
SLC34A2 functions as an oncogene in bladder cancer

W Ye et al

**Figure 6** MiR-214 is a negative regulator of SLC34A2. (a) Illustration of screening miRNAs regulating SLC34A2. Method #1 used the prediction algorithm of MICRORNA. ORG identified 23 miRNAs, which hold potential as SLC34A2 suppressors. Method #2 used miRNA profiling and identified 17 miRNAs, which were downregulated significantly in BC. Then, we overlapped the results of two methods and singled out miR-214 as a potential regulator. (b) Quantitative RT-PCR assay of miR-214 expression in four BC cell lines and three normal bladder tissues (N) (left panel), and in five pairs of matched BC (T) and adjacent non-neoplastic bladder tissue (ANT) (right panel). The average expression level of miR-214 in N or ANT was used as a loading control in quantitative RT-PCR assay. (c) Predicted miR-214 target sequence in 3′-UTR of SLC34A2 (SLC34A2 3′-UTR) and mutant miRNA containing three altered nucleotides in the seed sequence of miR-214 (miR-214-mut). (d) Luciferase assay of pGL3-3′SLC34A2 3′-UTR reporters co-transfected with increasing amounts (10, 20 and 50 nM) of miR-214 mimic or miR-214-mut in EJ and T24 cell lines. (e) Western blotting analysis demonstrates that miR-214 transfection markedly decreased SLC34A2 protein levels of EJ and T24 cells, whereas miR-214-mut exerted no inhibition effect. *P<0.05

**BC sample selection.** Tumor tissues collected from 156 BC patients were formalin-fixed and paraffin-embedded (FFPE). These patients were enrolled from the Department of Urology at The First Affiliated Hospital of Sun Yat-Sen University and The Hospital of Guangdong Province where they underwent radical cystectomy between January 2003 and December 2008. Fifty paraffin-embedded specimens of ANT from the same BC patients were used as controls. In addition, five fresh pairs of BC tissues and matched ANTs, as well as three specimens of normal bladder tissues from patients without BC-related disease were frozen and stored in liquid nitrogen until further use. In parallel, we obtained another independent validation cohort of FFPE samples from 130 BC patients who underwent radical cystectomy from the Department of Urology of Sun Yat-Sen University Cancer Center (Guangzhou, China) between March 2003 and February 2008. All the BC patients enrolled had no radio-chemical therapy histories before surgery. Clinical data were collected from raw case reports and staged according to the World Health Organization and the sixth edition of pTNM classification of the Union for International Cancer Control (UICC, 2002). All the patients were followed up on regular basis and the OS was defined as the time from surgery to the date of the death date or when censured at the latest date if patients were still alive. The clinicopathologic characteristics of the patients in each cohort are summarized in Table 1. Samples were obtained after given informed consent in accordance with the approval by institutional ethical review board.

**IHC staining assays and selecting the optimal cutoff value.** IHC staining assays were performed on 4-μm-thick FFPE sections. Briefly, sections were de-waxed, boiled in retrieval buffer solution for antigen recovery and then incubated with primary antibody overnight at 4 °C, followed by the Dako Real Envision Kit (Dako, Glostrup, Denmark), which was used to visualize protein expression. The intensity of staining in tumor cells was scored by two pathologists independently. First, tumor cells in five fields were randomly selected and scored based on the percentage of positively stained cells ranging from 0 to 100%. Then, the positive staining cells of different intensities were assessed: 0, no staining; 1, weak (light yellow); 2, moderate (yellow brown); 3, strong (brown). Finally, a semiquantitative IHC score ranging from 0 to 3 was calculated by multiplying the percentage of positively stained cells with each category of staining intensity.

The optimal cutoff IHC score of SLC34A2 expression was selected using X-tile plots (Yale University School of Medicine, New Haven, CT, USA). At first, we applied the X-tile program software to generate the optimal SLC34A2 IHC cutoff score to accurately classify patients according to clinical outcome in the training cohort. In the validation cohort, the cutoff score derived from X-tile analysis was investigated to exam the association of SLC34A2 expression with patients overall survival. X-tile data were presented in a right triangular grid where each point represents a different cut point. The intensity of the color of each cutoff point represents the strength of the association. The X-tile program can automatically select the optimal data cut point according to the highest chi-square value (minimum P-value) defined by Kaplan–Meier survival analysis and log-rank test. X-tile plots were performed with X-tile software version 3.6.1 (Yale University School of Medicine, New Haven, CT, USA).

**Statistical analysis.** All *in vitro* experiments were repeated at least three times. Statistical analyses were performed using the SPSS Standard version 16.0 software package (SPSS Inc., Chicago, IL, USA). ROC curve analysis was
conducted to evaluate the predictive value of the parameters. Kaplan–Meier and log-rank tests were used to analyze patient survival, and \( p \)-tests were used to analyze the associations between SLC34A2 expression and clinical–pathological parameters. Comparisons between groups for statistical significance were performed with a two-tailed paired Student's\( t\)-test. Bivariate correlations between study variables were calculated by Pearson's correlation coefficients. Data are presented as mean ± S.D. \( p\)-values < 0.05 were considered statistically significant.

Other Materials and methods are available in the Supplementary Materials and Methods.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements
This work was supported by the Natural Science Foundation of China (no. 81401991, no. 81225018 and no.81572359).

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1983–1987.
2. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004; 90: 2157–2166.
3. Wang L, Fu D, Qiu Y, Xing X, Xu F, Han C et al. Genome-wide screening and identification of long noncoding RNAs and their interaction with protein coding RNAs in bladder urothelial cell carcinoma. Cancer Lett 2014; 349: 77–86.
4. Zhang J, Wei J, Lu J, Tong Z, Liao B, Yu B et al. Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial-mesenchymal transition and activation of Akt/GSK-3beta/Snail signaling. Carcinogenesis 2013; 34: 2401–2408.
5. Traebert M, Hattenhauer O, Murer H, Kaissling B, Biber J. Expression of type II Na-P(i) cotransporter in alveolar type II cells. Am J Physiol 1999; 277: L686–L673.
6. Hashimoto M, Wang DY, Kamo T, Zhu Y, Tsujiuchi T, Konishi Y et al. Isolation and localization of type IIb NaPi cotransporter in the developing rat lung. Am J Pathol 2000; 157: 21–27.
7. Xu H, Bai L, Collins JF, Ghishan FK. Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2). Genomics 1999; 62: 281–284.
8. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S et al. Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. Hybridoma (2000) 2008; 27: 277–284.
9. Yin BW, Kyamova R, Chua R, Caballerio OL, Gout I, Gryshkova V et al. Monoclonal antibody MxK3 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun 2008; 8: 3.
10. Lopes dos Santos M, Yeda FP, Teuruda LR, Horta BB, Pimenta AA Jr., Degaki TL et al. Rebmate001, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted therapy of bladder cancer. PloS ONE 2013; 8: e70332.
11. Kang CV, MYC on the path to cancer. Cell 2012; 149: 22–35.
12. Stire ZE, Walton ZE, Atman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Disc 2015; 5: 1024–1039.
13. Amir S, Majeebsen NJ. microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. Histoxytopathol’2017; 32: 107–119.
14. Enokido H, Yashiro H, Matsuhashi R, Nakagawa M. The role of microRNAs in bladder cancer. Invest Clin Urol 2016; 57: 560–576.
15. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012; 61: 278–289.
16. Camp RL, Doolid-Ilhart M, Rimm DL, X-liite: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252–7259.
17. Raeside DE. Monte Carlo principles and applications. Phys Med Biol 1978; 21: 181–197.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/